JB Chem & Pharma

₹1953.7 -5.5 | 0.3%

WEBSITE BSE:506943 NSE : J.B.CHEMICAL 23 Mar, 16:01

Market Cap ₹14996 Cr.

Stock P/E 37.1

P/B 6.2

Current Price ₹1953.7

Book Value ₹ 312.9

Face Value 2

52W High ₹2149.9

Dividend Yield 0.85%

52W Low ₹ 1342.2

Edit Ratio

JB Chem & Pharma Research see more...

JB Chemicals: Business Analysis

Overview Inc. Year: 1976Industry: Pharmaceuticals & Drugs

J. B. Chemicals & Pharmaceuticals Ltd is an pharmaceutical company. It is an incorporated, research-orientated organization, which is focused on imparting products both in India and International markets. The Company manufactures and markets a range of herbal remedies, pharmaceutical formulations, active pharmaceutical ingredient (APIs). The Company is engaged in manufacturing distinctiveness merchandise that comprises various pharmaceutical dosage forms like drugs, injectable (vials, ampoules, form fill seal), creams & ointments, lozenges, liquids and pills. The Company's brands include Rantac (anti-peptic ulcerant), Cilacar (calcium channel blocker), Nicardia (calcium channel blocker) and Metrogyl (amoebicides).

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

JB Chem & Pharma Quarterly Results

#(Fig in Cr.)	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022
Net Sales	444	548	528	606	593	601	625	785	809	793
Other Income	8	56	25	13	20	5	2	1	1	3
Total Income	452	604	554	619	613	605	627	786	811	796
Total Expenditure	333	377	405	442	466	473	500	612	625	618
Operating Profit	118	227	149	177	146	133	127	174	186	178
Interest	2	1	1	1	1	1	2	6	8	8
Depreciation	17	17	17	18	16	17	22	26	28	28
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	0	0
Profit Before Tax	99	208	132	158	129	114	103	142	150	141
Provision for Tax	25	54	31	39	32	30	18	37	39	35
Profit After Tax	74	154	101	119	98	84	85	105	111	106
Adjustments	-0	-0	-0	-0	-0	-0	-0	-0	0	0
Profit After Adjustments	74	154	101	119	98	84	85	105	111	106
Adjusted Earnings Per Share	9.6	19.9	13	15.4	12.6	10.9	11	13.6	14.4	13.7

JB Chem & Pharma Profit & Loss

#(Fig in Cr.)	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	TTM
Net Sales	802	866	1022	1144	1232	1368	1414	1643	1775	2043	2424	3012
Other Income	29	28	38	11	57	54	55	41	51	117	40	7
Total Income	831	894	1060	1155	1288	1422	1469	1685	1826	2159	2464	3020
Total Expenditure	702	760	874	964	1026	1140	1215	1337	1397	1486	1882	2355
Operating Profit	129	134	186	191	263	283	254	347	428	673	583	665
Interest	24	5	6	7	11	5	3	5	3	7	5	24
Depreciation	22	25	28	39	41	47	57	56	66	69	73	104
Exceptional Income / Expenses	761	0	-65	0	0	0	0	0	-10	0	0	0
Profit Before Tax	843	104	87	146	211	230	194	287	349	597	505	536
Provision for Tax	166	24	26	45	50	46	55	93	77	148	119	129
Profit After Tax	678	79	61	100	161	184	139	194	272	449	386	407
Adjustments	0	0	0	0	1	-0	-0	-1	-0	-1	-1	0
Profit After Adjustments	678	79	61	100	163	184	138	193	272	448	385	407
Adjusted Earnings Per Share	80	9.4	7.3	11.8	19.2	21.7	16.6	24.1	35.2	58	49.9	52.7

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	19%	14%	12%	12%
Operating Profit CAGR	-13%	19%	16%	16%
PAT CAGR	-14%	26%	16%	-5%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	23%	63%	47%	39%
ROE Average	20%	22%	18%	20%
ROCE Average	25%	29%	24%	25%

JB Chem & Pharma Balance Sheet

#(Fig in Cr.)	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022
Shareholder's Funds	970	1020	1043	995	1184	1364	1442	1480	1435	1810	2134
Minority's Interest	0	0	0	0	2	2	3	3	3	4	4
Borrowings	13	7	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	27	33	31	32	31	27	46	65	63	72	79
Total Current Liabilities	188	239	276	460	797	693	736	782	516	687	852
Total Liabilities	1198	1300	1351	1487	2014	2086	2226	2329	2017	2572	3069
Fixed Assets	276	334	311	329	440	679	640	621	651	634	1277
Other Non-Current Assets	55	22	60	258	391	200	78	120	90	45	49
Total Current Assets	866	944	981	901	1182	1207	1509	1589	1276	1894	1743
Total Assets	1198	1300	1351	1487	2014	2086	2226	2329	2017	2572	3069

JB Chem & Pharma Cash Flow

#(Fig in Cr.)	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022
Opening Cash & Cash Equivalents	127	220	156	12	-5	7	-21	21	32	26	22
Cash Flow from Operating Activities	880	84	-14	127	140	201	123	194	276	315	170
Cash Flow from Investing Activities	-261	-116	-142	-112	-28	-45	-21	-28	24	-231	2
Cash Flow from Financing Activities	-526	-31	12	-1	-100	-184	-60	-156	-306	-87	-138
Net Cash Inflow / Outflow	93	-63	-144	13	13	-28	43	11	-6	-3	34
Closing Cash & Cash Equivalent	220	156	12	25	9	-21	21	32	26	22	57

JB Chem & Pharma Ratios

#	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022
Earnings Per Share (Rs)	80.03	9.38	7.26	11.84	19.16	21.7	16.55	24.11	35.2	57.96	49.86
CEPS(Rs)	82.68	12.29	10.56	16.4	23.87	27.31	23.42	31.11	43.83	66.92	59.35
DPS(Rs)	41	3	3	14	5	1	2	5	11	16.5	16.5
Book NAV/Share(Rs)	113.34	119.21	123.07	117.31	139.57	160.77	172.5	184.47	185.75	234.17	268.04
Core EBITDA Margin(%)	12.4	12.05	14.33	15.54	16.73	16.72	14.09	18.61	21.28	27.23	22.38
EBIT Margin(%)	107.19	12.42	9.03	13.15	17.98	17.2	13.97	17.75	19.84	29.58	21.04
Pre Tax Margin(%)	104.22	11.82	8.45	12.56	17.12	16.8	13.72	17.47	19.66	29.22	20.83
PAT Margin (%)	83.77	9.06	5.95	8.66	13.09	13.48	9.81	11.8	15.35	21.96	15.92
Cash Profit Margin (%)	86.54	11.88	8.65	12	16.44	16.93	13.84	15.19	19.09	25.32	18.92
ROA(%)	61.71	6.36	4.64	7.08	9.21	8.99	6.43	8.52	12.53	19.55	13.69
ROE(%)	82.49	8.07	5.99	9.86	14.8	14.48	9.89	13.28	18.69	27.64	19.89
ROCE(%)	92.09	10.41	8.5	13.49	17.72	16.87	13.7	19.59	23.71	36.53	25.48
Receivable days	108.62	68.16	75.3	78.41	79.28	71.84	73.15	67.63	67.22	65.62	71.12
Inventory Days	47.97	42.8	42.16	44.83	50.12	51.77	53.43	50.81	53.31	55.59	57.02
Payable days	49.78	47.94	70.5	73.91	62.53	62.76	70.44	69.69	82.55	92.33	89.07
PER(x)	0.76	7.84	17.68	16.9	13.01	15.99	18.68	14.91	14.44	21.63	31.59
Price/Book(x)	0.54	0.62	1.04	1.71	1.79	2.16	1.79	1.95	2.74	5.35	5.88
Dividend Yield(%)	67.1	4.08	2.34	7	2	0.29	0.65	1.39	2.16	1.32	1.05
EV/Net Sales(x)	0.46	0.6	1.14	1.57	1.86	2.18	1.83	1.75	2.21	4.74	5.01
EV/Core EBITDA(x)	2.85	3.87	6.29	9.42	8.74	10.54	10.15	8.28	9.17	14.4	20.84
Net Sales Growth(%)	-9.98	8.01	17.98	11.97	7.64	11.1	3.32	16.23	8	15.09	18.69
EBIT Growth(%)	393.63	-87.45	-14.22	63.18	45.34	6.26	-16.09	47.71	20.75	71.55	-15.58
PAT Growth(%)	386.57	-88.28	-22.59	63.27	60.59	14.37	-24.77	39.83	40.43	64.66	-13.93
EPS Growth(%)	385.48	-88.28	-22.61	63.12	61.87	13.24	-23.72	45.66	45.99	64.66	-13.98
Debt/Equity(x)	0.07	0.05	0.09	0.13	0.16	0.04	0.02	0.02	0.02	0.02	0.01
Current Ratio(x)	4.6	3.94	3.55	1.96	1.48	1.74	2.05	2.03	2.47	2.76	2.05
Quick Ratio(x)	4.06	3.53	3.06	1.63	1.25	1.45	1.76	1.72	1.94	2.25	1.56
Interest Cover(x)	36.1	20.61	15.74	22.33	20.8	43.81	56.54	62.74	108.09	83.43	99.6
Total Debt/Mcap(x)	0.14	0.08	0.09	0.08	0.09	0.02	0.01	0.01	0.01	0	0

JB Chem & Pharma Shareholding Pattern

#	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022
Promoter	55.91	55.91	55.91	55.91	55.91	54	54	54	53.96	53.95
FII	7.25	7.87	7.54	8.37	8.74	9.12	9.22	8.85	8.66	8.8
DII	12.38	13.91	13.17	13.13	15.24	16.26	16.89	17.8	18.48	18.54
Public	24.47	22.31	23.38	22.58	20.12	20.62	19.89	19.35	18.91	18.71
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022
Promoter	4.32	4.32	4.32	4.32	4.32	4.17	4.17	4.17	4.17	4.17
FII	0.56	0.61	0.58	0.65	0.68	0.71	0.71	0.68	0.67	0.68
DII	0.96	1.08	1.02	1.01	1.18	1.26	1.31	1.38	1.43	1.43
Public	1.89	1.72	1.81	1.75	1.55	1.59	1.54	1.5	1.46	1.45
Others	0	0	0	0	0	0	0	0	0	0
Total	7.73	7.73	7.73	7.73	7.73	7.73	7.73	7.73	7.73	7.74